EmboCept® S
degradable starch microspheres

KLINISCH RELEVANTE DATEN IN DER REGIONALEN TUMORTHERAPIE BEI CRC LEBERMETASTASEN

VERLEIHUNG DES MATTHIAS-LORENZ-FORSCHUNGSPREISES

DATUM: Freitag, 11. Januar 2019
ZEIT: 16:00 - 16:50 Uhr
RAUM: B 05-07
ORT: IROS, BCC Berlin Congress Center

VORSITZ: T. Vogl | J. Ebert

AGENDA:

16:00

Erste prospektive randomisierte Studie zur verbesserten Tumorresponse bei CRC: Der direkte Vergleich zwischen DSM-TACE und cTACE

T. Vogl, Frankfurt a. M.

16:15

Klinische Relevanz von DSM-TACE bei CRC im Vergleich zu TARE

D. Arnold, Hamburg

16:30

Verleihung des Matthias-Lorenz-Forschungspreises

J. Ebert, Berlin

16:35

Targeting of drug-loaded nanoparticles to tumor sites increases cell death and release danger signals

C. Janko, Erlangen

PharmaCept GmbH
Bessemerstr. 82
D-12103 Berlin

PharmaCept
www.pharmacept.com

EmboCept® S

degradable starch microspheres

UNIVERSAL SHORT-TERM* EMBOLIC AGENT IN DSM-TACE FOR LOCOREGIONAL TUMOR THERAPY.

*half-life 35 min



α-amylase

- excellent necrosis rates [1,2]
- higher intra-tumor concentration [3,4]
- combinable with many cytostatics [5,6]
- unlimitedly repeatable DSM-TACE [7,8]
- better tolerability [9]
- easy handling without long preparation time [10]

DSM-TACE = degradable starch microspheres - transarterial chemoembolisation

1: Ziemann, C. et al.: Inhibition of tumor growth of colorectal liver metastases after transarterial chemoembolization using different chemoembolisats in rat model, presentation at Deutscher Krebskongress 2014. 2: Altomonte J. et al.: Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology. 2008 Dec; 48(6):1864-73. 3: Pohlen. U. et al.: Increased carboplatin concentration in liver tumors through temporary flow retardation with starch microspheres (Spherex) and gelatin powder (Gelfoam): An experimental study in liver tumor-bearing rabbits, Journal of Surgical Research 92, 2000, 165-170. 4: Pohlen, U. et al.: Stealth liposomal 5-fluorouracil with or without degradable starch microspheres for hepatic arterial infusion in the treatment of liver metastases. An animal study in VX-2 liver tumor-bearing rabbits. Anticancer Res. 2004 May-Jun; 24(3a):1699-704. 5: Schicho, A. et al.: Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in Intrahepatic Cholangiocellular Carcinoma (ICC). Results from a National Multi-Center Study on Safety and Efficacy. 2017 In: Med. Sci. Monit. 23, S. 796–800. DOI: 10.12659/MSM.902901. 6: Schicho A. et al.: Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies. Onco Targets Ther. 2018 Jan 12;11:345-350. DOI: 10.2147/OTT.S147852 PMID: 9391811. 7: Vogl, T. et al.: Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: Local control and survival results, 2013, European Journal of Radiology 82, 258– 263. 8: Azizi, A. et.al.: Liver metastases of pancreatic cancer: role of repetitive transarterial chemoembolization (TACE) on tumor response and survival. 2011, In: Pancreas 40 (8), S. 1271–1275. DOI: 10.1097/MPA.0b013e318220e5b9. 9: Schlee, V. et al.: Komplikationen und unerwünschte Wirkungen im Rahmen intraarterieller Tumortherapien. Inauguraldissertation, Medizinische Fakultät, Universität Bonn (Betreuer: Layer G), 1999. 10: Instructions for Use EmboCept® S, date of information: 30.06.2017.